Michael P. Dube

CIK: 0002019493

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (77.8%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (22.2%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NTLA

Intellia Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

NTLA
Intellia Therapeutics, Inc.
Oct 2, 2026
Sale(S)
Direct
1.9K shares at avg. $12.43$23K
NTLA
Intellia Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
2.6K shares at avg. $16.78$44K
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2026
Award(A)
Direct
17.3K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
3K shares at avg. $9.21$28K
NTLA
Intellia Therapeutics, Inc.
Oct 1, 2025
Sale(S)
Direct
1.9K shares at avg. $17.38$33K
NTLA
Intellia Therapeutics, Inc.
Jul 2, 2025
Sale(S)
Direct
2.5K shares at avg. $9.95$25K
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2025
Award(A)
Direct
14K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 3, 2025
Sale(S)
Direct
1.4K shares at avg. $12.18$17K
NTLA
Intellia Therapeutics, Inc.
Oct 2, 2024
Sale(S)
Direct
2K shares at avg. $19.01$38K

		Type	Shares	Price		Ownership
Oct 2, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	1,864	$12.43	$23,170	Direct
Jul 1, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	2,641	$16.78	$44,316	Direct
Mar 1, 2026	NTLA Intellia Therapeutics, Inc.	Award(A)	17,250	-	$0	Direct
Jan 5, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	2,989	$9.21	$27,529	Direct
Oct 1, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	1,871	$17.38	$32,518	Direct
Jul 2, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	2,503	$9.95	$24,905	Direct
Mar 1, 2025	NTLA Intellia Therapeutics, Inc.	Award(A)	14,000	-	-	Direct
Jan 3, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	1,372	$12.18	$16,711	Direct
Oct 2, 2024	NTLA Intellia Therapeutics, Inc.	Sale(S)	2,012	$19.01	$38,248	Direct

1-9 of 9 transactions

About Dube Michael P

Dube Michael P (SEC CIK 0002019493) files insider reports with the SEC as VP, Chief Accounting Officer of Intellia Therapeutics, Inc. (NTLA).

Signal8 holds 9 ownership filings by Dube Michael P, all Form 4s, filed between Oct 4, 2024 and Oct 6, 2026. Those filings report 9 transactions, from Oct 2, 2024 to Oct 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Dube Michael P's filings is in CAMBRIDGE, MA.

Recent filings by Dube Michael P

Oct 2, 2026: Open-market sale of NTLA shares (Form 4, code S).
Jul 1, 2026: Open-market sale of NTLA shares (Form 4, code S).
Mar 1, 2026: Grant or award of NTLA shares (Form 4, code A).
Jan 5, 2026: Open-market sale of NTLA shares (Form 4, code S).
Oct 1, 2025: Open-market sale of NTLA shares (Form 4, code S).

Other insiders filing for Intellia Therapeutics, Inc. (NTLA)

Marantz Jing L., EVP, Chief Medical Officer
LEONARD JOHN M, President and CEO
Dulac Edward J III, EVP, Chief Financial Officer
Verwiel Frank, Director
Keresty Georgia, Director
GOODMAN JESSE, Director

How to read Form 4 transaction codes